Establishment of standard treatment for pancreatic ductal adenocarcinoma with peritoneal metastasis

JRCT ID: jRCTs051180199

Registered date:26/03/2019

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Invasive ductal adenocarcinoma
• Date of first enrollment: 26/02/2020
• Target sample size: 180
• Study type: Interventional
• Intervention(s): Anti-cancer drug administration

Outcome(s)

• Primary Outcome: Overall Survival
• Secondary Outcome: Response rate, negative rate of peritoneal lavage cytology, symptom relief effect, resectability, relative dose intensity, progression-free survival, decreasing rate of tumor marker, safety

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: < 80age old
• Gender: Both
• Include criteria: Patients with peritoneal metastasis without other organ metastases
• Exclude criteria: Cytology positive in patients with resectable/borderiline resectable pancreatic ductal adenocarcinoma

Related Information

• Primary Sponsor: Satoi Sohei
• Secondary ID(s): UMIN000027229